EXFORGE HCT 5 mg/160 mg/25 mg, film-coated tablet 30 tablets
Active ingredients: Amlodipine, Amlodipine besylate, HYDROCHLOROTHIAZIDE, Valsartan
Commercialized according to BDPMDispensing in France: Prescription only
Film-coated tablet30 tabletsorale
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- EXFORGE HCT 5 mg/160 mg/25 mg, comprimé pelliculé
- Pharmaceutical form
- comprimé pelliculé
- Route of administration
- orale
- Presentation description
- plaquette(s) PVC PVDC de 30 comprimé(s)
- Marketing authorisation holder
- NOVARTIS EUROPHARM (IRLANDE)
- Reimbursement according to BDPM
- —
- Approval for use in healthcare institutions
- non
- Commercialization declaration date
- 4 Aug 2025
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
63945271CIP73973335CIP133400939733357Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| HYDROCHLOROTHIAZIDEcomprimé | 25 mg · un comprimé | SA |
| VALSARTANcomprimé | 160 mg · un comprimé | SA |
| AMLODIPINEcomprimé | 5 mg · un comprimé | FT |
| BÉSILATE D'AMLODIPINEcomprimé | 6,94 mg · un comprimé | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.